BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23090068)

  • 1. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.
    Neumeister VM; Anagnostou V; Siddiqui S; England AM; Zarrella ER; Vassilakopoulou M; Parisi F; Kluger Y; Hicks DG; Rimm DL
    J Natl Cancer Inst; 2012 Dec; 104(23):1815-24. PubMed ID: 23090068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
    Yildiz-Aktas IZ; Dabbs DJ; Bhargava R
    Mod Pathol; 2012 Aug; 25(8):1098-105. PubMed ID: 22460807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, and c-erbB-2 oncoprotein in cytologic specimens: a simplified method with formalin fixation.
    Suthipintawong C; Leong AS; Chan KW; Vinyuvat S
    Diagn Cytopathol; 1997 Aug; 17(2):127-33. PubMed ID: 9258620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
    Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
    J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
    Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
    Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.
    Vassilakopoulou M; Parisi F; Siddiqui S; England AM; Zarella ER; Anagnostou V; Kluger Y; Hicks DG; Rimm DL; Neumeister VM
    Lab Invest; 2015 Mar; 95(3):334-41. PubMed ID: 25418580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index.
    Arima N; Nishimura R; Osako T; Nishiyama Y; Fujisue M; Okumura Y; Nakano M; Tashima R; Toyozumi Y
    J Clin Pathol; 2016 Mar; 69(3):255-9. PubMed ID: 26420767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
    Pinhel IF; Macneill FA; Hills MJ; Salter J; Detre S; A'hern R; Nerurkar A; Osin P; Smith IE; Dowsett M
    Breast Cancer Res; 2010; 12(5):R76. PubMed ID: 20920193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of antigenicity with tissue age in breast cancer.
    Combs SE; Han G; Mani N; Beruti S; Nerenberg M; Rimm DL
    Lab Invest; 2016 Mar; 96(3):264-9. PubMed ID: 26568292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer.
    Wang X; Liu D; Zeng X; Jiang S; Li L; Yu T; Zhang J
    Cancer Imaging; 2021 Jan; 21(1):4. PubMed ID: 33413654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach.
    Leal MF; Haynes BP; MacNeill FA; Dodson A; Dowsett M
    Breast Cancer Res Treat; 2019 Jun; 175(2):317-326. PubMed ID: 30796652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neoadjuvant therapy on breast cancer biomarker profile.
    Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
    BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid triage protocol to optimize cold ischemic time for breast resection specimens.
    East EG; Gabbeart M; Roberts E; Zhao L; Jorns JM
    Ann Diagn Pathol; 2018 Jun; 34():94-97. PubMed ID: 29661737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.
    Schink JC; Trosman JR; Weldon CB; Siziopikou KP; Tsongalis GJ; Rademaker AW; Patel JD; Benson AB; Perez EA; Gradishar WJ
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
    Xian Z; Quinones AK; Tozbikian G; Zynger DL
    Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time.
    Ehinger A; Bendahl PO; Rydén L; Fernö M; Alkner S
    APMIS; 2018 Sep; 126(9):746-754. PubMed ID: 30160021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.